Report Detail
Global Tumour Neoantigens Market Growth 2022-2028
- RnM4497996 |
- 08 December, 2022 |
- Global |
- 103 Pages |
- LPI(LP Information) |
- Pharma & Healthcare
Tumor neoantigens, as their name implies, are antigens that are not expressed in normal tissues but are expressed only in tumor tissues, including those produced by the integration of oncogenic viruses into the genome and mutant proteins, and neoantigens are not only highly specific but also strongly immunogenic because of their unselected thymus negative screening.
The global market for Tumour Neoantigens is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Tumour Neoantigens market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Tumour Neoantigens market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Tumour Neoantigens market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Tumour Neoantigens market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Tumour Neoantigens players cover Achilles Therapeutics plc, Advaxis Immunotherapies, Genocea, Gradalis, Inc and Gritstone bio, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Tumour Neoantigens market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Tumour Neoantigens market, with both quantitative and qualitative data, to help readers understand how the Tumour Neoantigens market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.
Market Segmentation:
The study segments the Tumour Neoantigens market and forecasts the market size by Type (Common Neoantigens and Individualized Neoantigens,), by Application (T Cell Adoptive Therapy, DC Therapy, Therapeutic Vaccines and Other), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Common Neoantigens
Individualized Neoantigens
Segmentation by application
T Cell Adoptive Therapy
DC Therapy
Therapeutic Vaccines
Other
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
Achilles Therapeutics plc
Advaxis Immunotherapies
Genocea
Gradalis, Inc
Gritstone bio
Iovance Biotherapetics Inc
Medigene AG
BioNTech SE
Lilly
Scicomvisuals
Moderna, Inc
F. Hoffmann-La Roche Ltd
Merck KGaA
Sun Pharmaceutical Industries Ltd
Chapter Introduction
Chapter 1: Scope of Tumour Neoantigens, Research Methodology, etc.
Chapter 2: Executive Summary, global Tumour Neoantigens market size (sales and revenue) and CAGR, Tumour Neoantigens market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Tumour Neoantigens sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Tumour Neoantigens sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Tumour Neoantigens market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Achilles Therapeutics plc, Advaxis Immunotherapies, Genocea, Gradalis, Inc, Gritstone bio, Iovance Biotherapetics Inc, Medigene AG, BioNTech SE and Lilly, etc.
Chapter 14: Research Findings and Conclusion
1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Tumour Neoantigens Annual Sales 2017-2028
- 2.1.2 World Current & Future Analysis for Tumour Neoantigens by Geographic Region, 2017, 2022 & 2028
- 2.1.3 World Current & Future Analysis for Tumour Neoantigens by Country/Region, 2017, 2022 & 2028
- 2.2 Tumour Neoantigens Segment by Type
- 2.2.1 Common Neoantigens
- 2.2.2 Individualized Neoantigens
- 2.3 Tumour Neoantigens Sales by Type
- 2.3.1 Global Tumour Neoantigens Sales Market Share by Type (2017-2022)
- 2.3.2 Global Tumour Neoantigens Revenue and Market Share by Type (2017-2022)
- 2.3.3 Global Tumour Neoantigens Sale Price by Type (2017-2022)
- 2.4 Tumour Neoantigens Segment by Application
- 2.4.1 T Cell Adoptive Therapy
- 2.4.2 DC Therapy
- 2.4.3 Therapeutic Vaccines
- 2.4.4 Other
- 2.5 Tumour Neoantigens Sales by Application
- 2.5.1 Global Tumour Neoantigens Sale Market Share by Application (2017-2022)
- 2.5.2 Global Tumour Neoantigens Revenue and Market Share by Application (2017-2022)
- 2.5.3 Global Tumour Neoantigens Sale Price by Application (2017-2022)
3 Global Tumour Neoantigens by Company
- 3.1 Global Tumour Neoantigens Breakdown Data by Company
- 3.1.1 Global Tumour Neoantigens Annual Sales by Company (2020-2022)
- 3.1.2 Global Tumour Neoantigens Sales Market Share by Company (2020-2022)
- 3.2 Global Tumour Neoantigens Annual Revenue by Company (2020-2022)
- 3.2.1 Global Tumour Neoantigens Revenue by Company (2020-2022)
- 3.2.2 Global Tumour Neoantigens Revenue Market Share by Company (2020-2022)
- 3.3 Global Tumour Neoantigens Sale Price by Company
- 3.4 Key Manufacturers Tumour Neoantigens Producing Area Distribution, Sales Area, Product Type
- 3.4.1 Key Manufacturers Tumour Neoantigens Product Location Distribution
- 3.4.2 Players Tumour Neoantigens Products Offered
- 3.5 Market Concentration Rate Analysis
- 3.5.1 Competition Landscape Analysis
- 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
- 3.6 New Products and Potential Entrants
- 3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Tumour Neoantigens by Geographic Region
- 4.1 World Historic Tumour Neoantigens Market Size by Geographic Region (2017-2022)
- 4.1.1 Global Tumour Neoantigens Annual Sales by Geographic Region (2017-2022)
- 4.1.2 Global Tumour Neoantigens Annual Revenue by Geographic Region
- 4.2 World Historic Tumour Neoantigens Market Size by Country/Region (2017-2022)
- 4.2.1 Global Tumour Neoantigens Annual Sales by Country/Region (2017-2022)
- 4.2.2 Global Tumour Neoantigens Annual Revenue by Country/Region
- 4.3 Americas Tumour Neoantigens Sales Growth
- 4.4 APAC Tumour Neoantigens Sales Growth
- 4.5 Europe Tumour Neoantigens Sales Growth
- 4.6 Middle East & Africa Tumour Neoantigens Sales Growth
5 Americas
- 5.1 Americas Tumour Neoantigens Sales by Country
- 5.1.1 Americas Tumour Neoantigens Sales by Country (2017-2022)
- 5.1.2 Americas Tumour Neoantigens Revenue by Country (2017-2022)
- 5.2 Americas Tumour Neoantigens Sales by Type
- 5.3 Americas Tumour Neoantigens Sales by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil
6 APAC
- 6.1 APAC Tumour Neoantigens Sales by Region
- 6.1.1 APAC Tumour Neoantigens Sales by Region (2017-2022)
- 6.1.2 APAC Tumour Neoantigens Revenue by Region (2017-2022)
- 6.2 APAC Tumour Neoantigens Sales by Type
- 6.3 APAC Tumour Neoantigens Sales by Application
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan
7 Europe
- 7.1 Europe Tumour Neoantigens by Country
- 7.1.1 Europe Tumour Neoantigens Sales by Country (2017-2022)
- 7.1.2 Europe Tumour Neoantigens Revenue by Country (2017-2022)
- 7.2 Europe Tumour Neoantigens Sales by Type
- 7.3 Europe Tumour Neoantigens Sales by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
8 Middle East & Africa
- 8.1 Middle East & Africa Tumour Neoantigens by Country
- 8.1.1 Middle East & Africa Tumour Neoantigens Sales by Country (2017-2022)
- 8.1.2 Middle East & Africa Tumour Neoantigens Revenue by Country (2017-2022)
- 8.2 Middle East & Africa Tumour Neoantigens Sales by Type
- 8.3 Middle East & Africa Tumour Neoantigens Sales by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Tumour Neoantigens
- 10.3 Manufacturing Process Analysis of Tumour Neoantigens
- 10.4 Industry Chain Structure of Tumour Neoantigens
11 Marketing, Distributors and Customer
- 11.1 Sales Channel
- 11.1.1 Direct Channels
- 11.1.2 Indirect Channels
- 11.2 Tumour Neoantigens Distributors
- 11.3 Tumour Neoantigens Customer
12 World Forecast Review for Tumour Neoantigens by Geographic Region
- 12.1 Global Tumour Neoantigens Market Size Forecast by Region
- 12.1.1 Global Tumour Neoantigens Forecast by Region (2023-2028)
- 12.1.2 Global Tumour Neoantigens Annual Revenue Forecast by Region (2023-2028)
- 12.2 Americas Forecast by Country
- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global Tumour Neoantigens Forecast by Type
- 12.7 Global Tumour Neoantigens Forecast by Application
13 Key Players Analysis
- 13.1 Achilles Therapeutics plc
- 13.1.1 Achilles Therapeutics plc Company Information
- 13.1.2 Achilles Therapeutics plc Tumour Neoantigens Product Offered
- 13.1.3 Achilles Therapeutics plc Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.1.4 Achilles Therapeutics plc Main Business Overview
- 13.1.5 Achilles Therapeutics plc Latest Developments
- 13.2 Advaxis Immunotherapies
- 13.2.1 Advaxis Immunotherapies Company Information
- 13.2.2 Advaxis Immunotherapies Tumour Neoantigens Product Offered
- 13.2.3 Advaxis Immunotherapies Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.2.4 Advaxis Immunotherapies Main Business Overview
- 13.2.5 Advaxis Immunotherapies Latest Developments
- 13.3 Genocea
- 13.3.1 Genocea Company Information
- 13.3.2 Genocea Tumour Neoantigens Product Offered
- 13.3.3 Genocea Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.3.4 Genocea Main Business Overview
- 13.3.5 Genocea Latest Developments
- 13.4 Gradalis, Inc
- 13.4.1 Gradalis, Inc Company Information
- 13.4.2 Gradalis, Inc Tumour Neoantigens Product Offered
- 13.4.3 Gradalis, Inc Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.4.4 Gradalis, Inc Main Business Overview
- 13.4.5 Gradalis, Inc Latest Developments
- 13.5 Gritstone bio
- 13.5.1 Gritstone bio Company Information
- 13.5.2 Gritstone bio Tumour Neoantigens Product Offered
- 13.5.3 Gritstone bio Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.5.4 Gritstone bio Main Business Overview
- 13.5.5 Gritstone bio Latest Developments
- 13.6 Iovance Biotherapetics Inc
- 13.6.1 Iovance Biotherapetics Inc Company Information
- 13.6.2 Iovance Biotherapetics Inc Tumour Neoantigens Product Offered
- 13.6.3 Iovance Biotherapetics Inc Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.6.4 Iovance Biotherapetics Inc Main Business Overview
- 13.6.5 Iovance Biotherapetics Inc Latest Developments
- 13.7 Medigene AG
- 13.7.1 Medigene AG Company Information
- 13.7.2 Medigene AG Tumour Neoantigens Product Offered
- 13.7.3 Medigene AG Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.7.4 Medigene AG Main Business Overview
- 13.7.5 Medigene AG Latest Developments
- 13.8 BioNTech SE
- 13.8.1 BioNTech SE Company Information
- 13.8.2 BioNTech SE Tumour Neoantigens Product Offered
- 13.8.3 BioNTech SE Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.8.4 BioNTech SE Main Business Overview
- 13.8.5 BioNTech SE Latest Developments
- 13.9 Lilly
- 13.9.1 Lilly Company Information
- 13.9.2 Lilly Tumour Neoantigens Product Offered
- 13.9.3 Lilly Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.9.4 Lilly Main Business Overview
- 13.9.5 Lilly Latest Developments
- 13.10 Scicomvisuals
- 13.10.1 Scicomvisuals Company Information
- 13.10.2 Scicomvisuals Tumour Neoantigens Product Offered
- 13.10.3 Scicomvisuals Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.10.4 Scicomvisuals Main Business Overview
- 13.10.5 Scicomvisuals Latest Developments
- 13.11 Moderna, Inc
- 13.11.1 Moderna, Inc Company Information
- 13.11.2 Moderna, Inc Tumour Neoantigens Product Offered
- 13.11.3 Moderna, Inc Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.11.4 Moderna, Inc Main Business Overview
- 13.11.5 Moderna, Inc Latest Developments
- 13.12 F. Hoffmann-La Roche Ltd
- 13.12.1 F. Hoffmann-La Roche Ltd Company Information
- 13.12.2 F. Hoffmann-La Roche Ltd Tumour Neoantigens Product Offered
- 13.12.3 F. Hoffmann-La Roche Ltd Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.12.4 F. Hoffmann-La Roche Ltd Main Business Overview
- 13.12.5 F. Hoffmann-La Roche Ltd Latest Developments
- 13.13 Merck KGaA
- 13.13.1 Merck KGaA Company Information
- 13.13.2 Merck KGaA Tumour Neoantigens Product Offered
- 13.13.3 Merck KGaA Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.13.4 Merck KGaA Main Business Overview
- 13.13.5 Merck KGaA Latest Developments
- 13.14 Sun Pharmaceutical Industries Ltd
- 13.14.1 Sun Pharmaceutical Industries Ltd Company Information
- 13.14.2 Sun Pharmaceutical Industries Ltd Tumour Neoantigens Product Offered
- 13.14.3 Sun Pharmaceutical Industries Ltd Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.14.4 Sun Pharmaceutical Industries Ltd Main Business Overview
- 13.14.5 Sun Pharmaceutical Industries Ltd Latest Developments
14 Research Findings and Conclusion
Summary:
Get latest Market Research Reports on Tumour Neoantigens. Industry analysis & Market Report on Tumour Neoantigens is a syndicated market report, published as Global Tumour Neoantigens Market Growth 2022-2028. It is complete Research Study and Industry Analysis of Tumour Neoantigens market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
